Unicycive Therapeutics, Inc. (UNCY) Misses Q2 EPS by 143c
Tweet
Share
E-mailGet Alerts UNCY Hot Sheet
Join SI Premium – FREE
Unicycive Therapeutics, Inc. (NASDAQ: UNCY) reported Q2 EPS of ($1.50), $1.43 worse than the analyst estimate of ($0.07).
For earnings history and earnings-related data on Unicycive Therapeutics, Inc. (UNCY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Concentrix Corporation (CNXC) Misses Q2 EPS by 1c; Guides lower than expectations
- FDA selects seven participants for precheck pilot program to advance U.S. drug manufacturing
- Activist Ed Garden lauds new Fortune Brands CEO - Bloomberg
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
